StockData
AnaptysBio, Inc logo

AnaptysBio, Inc (ANAB) stock

ANABNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 9/30
$49.24+2.63 (+5.64%)

Close on Oct 19, 2026Market cap $2.28BP/E –Yield –

AnaptysBio free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

AnaptysBio's free cash flow for the twelve months ending Mar 31, 2026 was $4.41M. For fiscal 2025 it was $19.61M. The highest annual figure on record is $19.61M in fiscal 2025.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$19.61M–
FY2024Dec 31, 2024-$135.70M–
FY2023Dec 31, 2023-$121.61M–
FY2022Dec 31, 2022-$73.95M–
FY2021Dec 31, 2021-$47.29M–
FY2020Dec 31, 2020-$14.73M–
FY2019Dec 31, 2019-$70.32M–
FY2018Dec 31, 2018-$49.57M–
FY2017Dec 31, 2017-$19.73M–
FY2016Dec 31, 2016-$9.08M–
FY2015Dec 31, 2015-$9.93M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2026Mar 31, 2026-$25.94M–
Q4 FY2025Dec 31, 2025$98.00M–
Q3 FY2025Sep 30, 2025-$27.37M–
Q2 FY2025Jun 30, 2025-$40.28M–
Q1 FY2025Mar 31, 2025-$10.74M–
Q4 FY2024Dec 31, 2024-$66.94M–
Q3 FY2024Sep 30, 2024-$10.13M–
Q2 FY2024Jun 30, 2024-$21.36M–
Q1 FY2024Mar 31, 2024-$37.28M–
Q4 FY2023Dec 31, 2023-$34.63M–
Q3 FY2023Sep 30, 2023-$36.64M–
Q2 FY2023Jun 30, 2023-$25.60M–
Q1 FY2023Mar 31, 2023-$24.74M–
Q4 FY2022Dec 31, 2022-$10.86M–
Q3 FY2022Sep 30, 2022-$17.80M–
Q2 FY2022Jun 30, 2022-$24.23M-377.6%
Q1 FY2022Mar 31, 2022-$21.07M–
Q4 FY2021Dec 31, 2021-$25.32M-167.9%
Q3 FY2021Sep 30, 2021-$7.18M–
Q2 FY2021Jun 30, 2021$8.73M–
Q1 FY2021Mar 31, 2021-$23.52M–
Q4 FY2020Dec 31, 2020$37.27M–
Q3 FY2020Sep 30, 2020-$17.10M–
Q2 FY2020Jun 30, 2020-$19.69M–
Q1 FY2020Mar 31, 2020-$15.20M–
Q4 FY2019Dec 31, 2019-$15.91M–
Q3 FY2019Sep 30, 2019-$22.38M–
Q2 FY2019Jun 30, 2019-$15.76M–
Q1 FY2019Mar 31, 2019-$16.28M–
Q4 FY2018Dec 31, 2018-$12.50M–
Q3 FY2018Sep 30, 2018-$15.18M–
Q2 FY2018Jun 30, 2018-$9.18M–
Q1 FY2018Mar 31, 2018-$12.71M–
Q4 FY2017Dec 31, 2017-$4.93M–
Q3 FY2017Sep 30, 2017-$3.90M–
Q2 FY2017Jun 30, 2017-$2.71M–
Q1 FY2017Mar 31, 2017-$8.18M–
Q4 FY2016Dec 31, 2016-$5.57M–
Q3 FY2016Sep 30, 2016-$3.07M–

More AnaptysBio figures

See a number that looks wrong?